HUTCHMED (China) Ltd
sovleplenib
warm antibody autoimmune hemolytic anemia
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for sovleplenib in warm antibody autoimmune hemolytic anemia are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 13h ago
“Results from the Phase II part of the study published in The Lancet Haematology in January 2025 demonstrated encouraging hemoglobin benefit compared with placebo, with overall response rate of 43.8% vs 0% in the first 8 weeks, and overall r”